Dr. Galal on Managing AEs Linked With CAR T-Cell Therapy
Ahmed Galal, MD, instructor, Department of Medicine, Duke Cancer Institute, discusses the management of adverse events (AEs) associated with CAR T-cell therapy.
Dr. Galal on CAR T-Cell Therapy in Relapsed/Refractory Lymphomas
Ahmed Galal, MD, instructor, Department of Medicine, Duke Cancer Institute, discusses the use of CAR T-cell therapy in patients with relapsed/refractory lymphomas.
Dr. Galal on Ways of Extending the Reach of CAR T-Cell Therapy
Ahmed Galal, MD, instructor, Department of Medicine, Duke Cancer Institute, discusses ways of extending the reach of CAR T-cell therapy in real-world practice.
